



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/069,386	09/12/2002	Moulay A. Alaoui-Jamali	SWA-001US) 3268	
32254 7	7590 01/12/2006		EXAMINER	
KEOWN & ASSOCIATES			WHITEMAN, BRIAN A	
SUITE 1200	MMINGS PARK		ART UNIT	PAPER NUMBER
WOBURN, MA 01801			1635	
			DATE MAIL ED. 01/12/2006	

DATE MAILED: 01/12/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	Applicant(s)		
10/069,386	ALAOUI-JAMALI ET AL.	ALAOUI-JAMALI ET AL.		
Examiner	Art Unit			
Brian Whiteman	1635			

	Brian Whiteman	1635				
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress			
THE REPLY FILED 12/27/05 FAILS TO PLACE THIS APPLICA						
 The reply was filed after a final rejection, but prior to or of this application, applicant must timely file one of the follo places the application in condition for allowance; (2) a No. (3) a Request for Continued Examination (RCE) in completion following time periods: 	n the same day as filing a Notice o wing replies: (1) an amendment, a otice of Appeal (with appeal fee) in	f Appeal. To avoid at ffidavit, or other evide compliance with 37 (ence, which CFR 41.31; or			
a) \square The period for reply expires $\underline{5}$ months from the mailing date of	the final rejection.					
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.						
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).						
Extensions of time may be obtained under 37 CFR 1.136(a). The date on been filed is the date for purposes of determining the period of extension a CFR 1.17(a) is calculated from: (1) the expiration date of the shortened states above, if checked. Any reply received by the Office later than three months parned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	nd the corresponding amount of the fee. Itutory period for reply originally set in the	The appropriate extension final Office action; or (2)	on fee under 37 as set forth in (b)			
2. The Notice of Appeal was filed on A brief in composition of filing the Notice of Appeal (37 CFR 41.37(a)), or any e Since a Notice of Appeal has been filed, any reply must be a since of Appeal of the composition of the compositi	xtension thereof (37 CFR 41.37(e)), to avoid dismissal (of the appeal.			
<u>AMENDMENTS</u>						
3. The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co	nsideration and/or search (see NO		because			
(b) They raise the issue of new matter (see NOTE belo (c) They are not deemed to place the application in bet	• •	educing or simplifying	g the issues for			
appeal; and/or (d)☐ They present additional claims without canceling a	corresponding number of finally re	elected claims				
NOTE: See Continuation Sheet. (See 37 CFR 1.1		jeoted oldimis.				
4. The amendments are not in compliance with 37 CFR 1.1	, ,,	ompliant Amendmen	t (PTOL-324)			
5. Applicant's reply has overcome the following rejection(s		ompliant / monamen	((10L 0Z+).			
 Newly proposed or amended claim(s) would be a the non-allowable claim(s). 		, timely filed amendn	nent canceling			
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows:		vill be entered and an	explanation of			
Claim(s) allowed: <u>1,3 and 10</u> .						
Claim(s) objected to: 2 and 4.						
Claim(s) rejected: <u>6</u> . Claim(s) withdrawn from consideration: <u>11</u> .						
AFFIDAVIT OR OTHER EVIDENCE						
 The affidavit or other evidence filed after a final action, because applicant failed to provide a showing of good an and was not earlier presented. See 37 CFR 1.116(e). 	ut before or on the date of filing a N d sufficient reasons why the affida	Notice of Appeal will vit or other evidence	not be entered is necessary			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rejections under appe	al and/or appellant fa	ails to provide a			
10. ⊠ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	on of the status of the claims after	entry is below or atta	ched.			
11. The request for reconsideration has been considered by See Continuation Sheet.	at does NOT place the application i	in condition for allowa	ance because:			
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08 or PTO-1449) Paper	No(s)				
13. ⊠ Other: <u>See Continuation Sheet</u> .			_			

U.S. Patent and Trademark Office PTOL-303 (Rev. 7-05)

-Continuation Sheet (PTOL-303)

Application No.

Continuation of 3. NOTE: The proposed amendment to the claim would require further consideration under 112 first paragraph enablement, new matter, and second paragraph.

Continuation of 11, does NOT place the application in condition for allowance because: the argument for claim 6 is based on a proposed amendment that was not entered.

Continuation of 13. Other: The objection to the specification for introducing new matter into the specification and the 112 first paragraph new matter rejection for claims 2 and 4 are withdrawn in view of the Declaration by Dr. Alaoui-Jamali. The Declaration displays that SEQ ID NO: 1 and 2 were isolated from human cells as shown on page 7, lines 2-5. and the BLASTN search on page 6 only identified human ESTs. The Declaration further displays that the inventors were in possession of the human sequence before the filing date of the application.

In view of the Declaration, claims 2 and 4 are objected to because they do not further limit the claim from which they depend from. The nucleic acid encoding the amino acid sequence as set forth in SEQ ID NO: 2 as recited in claim 1 is from a human. The amino acid sequence as set forth in SEQ ID NO: 2 is from a human. Thus, Claims 2 and 4 are redundant